APR 22, 2016 12:16 PM PDT

Monocyte-Based Cell Therapy to Treat Macrophage Malfunction

WRITTEN BY: Kara Marker
Macrophages exist in every type of body tissue, in the lungs as alveolar macrophages and in the liver as Kupffer cells. With an incredible ability to specialize in function and a large self-maintenance capacity, it is easy to see how genetic or autoimmune predispositions to macrophage error could quickly result in a terrible, debilitating state of disease.
 
Macrophages engulf and destroy dead and dying cells as well as any pathogens that cross their path. These immune cells differentiate from monocytes early in their life and receive tissue-specific signals depending on the influence of their embryonic precursor. Some monocytes remain forever-young, circulating the blood waiting for an emergency call where they might be needed as back-up. Circulating monocytes do respond to recruiting signals when a tissue is under an uncontrollable amount of duress, but their differentiation into tissue-specific macrophages in response to the call only exists as ephemeral reinforcement.
 
"Macrophage Engulfing Bacteria, Artwork" by David Mack
 
Macrophages were discovered for the first time in 1882, and scientists are only now fully understanding the relationship between adult circulating monocytes and their tissue-specific relatives. In a series of studies published in both Immunity and Nature Communications, scientists from the Flanders Interuniversity Institute for Biotechnology and UGent showed using mouse models how adult circulating monocytes could exist alongside tissue-specific macrophages as equals if exposed to the right signals.
 
While the scientists involved in this study are still unsure about the nature of the signals required for monocytes to differentiate into permanent tissue-specific macrophages, they are hopeful that their discoveries could soon be used as monocyte-based treatments for diseases like pulmonary alveolar proteinosis (PAP), a rare blood disease characterized by malfunctioning of macrophages in the lungs.
 
PAP exists in three forms: congenital, secondary, and acquired, also known as idiopathic or primary. While different forms of the disease are characterized by different causative agents, the disease ultimately remains the same. Phospholipids and protein build up in the alveoli causing severe breathing problems and lung failure.
 
A large majority of PAP cases are acquired, a form of the disease caused by an autoimmune response where antibodies target a blood protein called granulocyte-macrophage colony stimulating factor for destruction. Instead of employing immunosuppressant drugs to halt the autoimmune response, monocyte-based therapy could be incorporated to refuel the lung’s population of macrophages.
 
Using mouse models, scientists involved in the present studies depleted the population of embryonic-derived Kupffer cells in the liver. Miraculously, blood monocytes rushed in to take the place of these macrophages, differentiating and appearing identical to the original macrophage population within two weeks.
 
Similarly, researchers saw both adult circulating monocytes and embryonic precursors differentiate into identical, tissue-specific macrophages when each population was injected into mice lungs lacking alveolar macrophages. The differentiated macrophages remained functional, self-maintained, and preventing disease for up to one year.
 
According to Nature Reviews Immunology, macrophages are “remarkably plastic and can change their functional phenotype depending on the environmental cues they receive.” Martin Guilliams, PhD, one of the scientists involved in the studies, realized the future ability of researchers to manipulate populations of tissue macrophages to treat diseases like PAP.
 
“These findings would predict the existence of a restricted number of macrophage niches per tissue,” he said.
 
Whether it’s curing PAP or another macrophage-associated disease, the future of monocyte-based therapy is extremely promising, especially since circulating monocytes are easily accessible from blood donations, while embryonic precursors to tissue-specific macrophages are not.
 

Source: Flanders Interuniversity Institute for Biotechnology, Pulmonary Alveolar Proteinosis Foundation, Nature Reviews Immunology, publications in Immunity, Nature Communications, and another in Immunity
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
DEC 31, 2021
Genetics & Genomics
Alzheimer's Risk Gene May Impair Neuroprotective Mechanism
DEC 31, 2021
Alzheimer's Risk Gene May Impair Neuroprotective Mechanism
Our bodies have some healing and regenerative capabilities. For most of us, cuts will mend, we'll recover from mild infe ...
JAN 06, 2022
Health & Medicine
New Hope for Hair Regrowth in Alopecia Areata
JAN 06, 2022
New Hope for Hair Regrowth in Alopecia Areata
Two recently completed phase 3 clinical trials showed the drug baricitinib leads to hair growth for alopecia areata pati ...
JAN 11, 2022
Technology
Does Consuming Different Types of Media Affect Mental Wellbeing?
JAN 11, 2022
Does Consuming Different Types of Media Affect Mental Wellbeing?
We’ve probably all been told that we need to be on our phones less. We’ve probably all seen those challenges ...
JAN 19, 2022
Genetics & Genomics
Targeting Proteins Linked to Huntington's & ALS With a New Gene Editing Tool
JAN 19, 2022
Targeting Proteins Linked to Huntington's & ALS With a New Gene Editing Tool
The CRISPR gene editing tool is often used with an enzyme called Cas9, which targets and cuts genomic DNA. While this te ...
JAN 20, 2022
Drug Discovery & Development
Review Finds Improved Transparency Among Antidepressant Drug Trials
JAN 20, 2022
Review Finds Improved Transparency Among Antidepressant Drug Trials
Trials relating to newly developed antidepressant drugs are becoming more transparent. The corresponding study was publi ...
JAN 26, 2022
Cell & Molecular Biology
An Antibacterial Molecule Links Chronic Inflammatory Disease & Gut Microbiome
JAN 26, 2022
An Antibacterial Molecule Links Chronic Inflammatory Disease & Gut Microbiome
The gut microbiome is crucial to human health, but the human body has to keep the microorganisms within it in check. We ...
Loading Comments...